{"brief_title": "A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients", "brief_summary": "To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.", "detailed_description": "A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Zidovudine", "criteria": "Inclusion Criteria Patients must have: - HIV antibody positive. - CD4 count >= 150 and <= 500 cells/mm3. Exclusion Criteria Prior Medication: Excluded: - Prior antiretroviral therapy. - Prior protease inhibitor therapy.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002190.xml"}